JP2022533711A5 - - Google Patents

Info

Publication number
JP2022533711A5
JP2022533711A5 JP2021569065A JP2021569065A JP2022533711A5 JP 2022533711 A5 JP2022533711 A5 JP 2022533711A5 JP 2021569065 A JP2021569065 A JP 2021569065A JP 2021569065 A JP2021569065 A JP 2021569065A JP 2022533711 A5 JP2022533711 A5 JP 2022533711A5
Authority
JP
Japan
Prior art keywords
progression
inhibiting
pharmaceutical composition
peptide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533711A (ja
JP7606471B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033996 external-priority patent/WO2020237050A1/en
Publication of JP2022533711A publication Critical patent/JP2022533711A/ja
Publication of JP2022533711A5 publication Critical patent/JP2022533711A5/ja
Application granted granted Critical
Publication of JP7606471B2 publication Critical patent/JP7606471B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569065A 2019-05-22 2020-05-21 Lag3結合ペプチド Active JP7606471B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851142P 2019-05-22 2019-05-22
US62/851,142 2019-05-22
PCT/US2020/033996 WO2020237050A1 (en) 2019-05-22 2020-05-21 Lag3 binding peptides

Publications (3)

Publication Number Publication Date
JP2022533711A JP2022533711A (ja) 2022-07-25
JP2022533711A5 true JP2022533711A5 (enExample) 2023-04-13
JP7606471B2 JP7606471B2 (ja) 2024-12-25

Family

ID=71078604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569065A Active JP7606471B2 (ja) 2019-05-22 2020-05-21 Lag3結合ペプチド

Country Status (6)

Country Link
US (2) US11407829B2 (enExample)
EP (1) EP3972696A1 (enExample)
JP (1) JP7606471B2 (enExample)
AU (1) AU2020279371A1 (enExample)
CA (1) CA3141162A1 (enExample)
WO (1) WO2020237050A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020237050A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
AU2021316230A1 (en) * 2020-07-31 2023-03-16 Leidos, Inc. LAG3 binding peptides
KR102942705B1 (ko) 2023-03-20 2026-03-27 경북대학교 산학협력단 Lag-3에 결합하는 펩타이드 및 이의 용도
EP4685152A1 (en) * 2023-03-20 2026-01-28 Kyungpook National University Industry-Academic Cooperation Foundation Peptide binding to lag-3 and use thereof
WO2025010238A2 (en) * 2023-07-03 2025-01-09 The Johns Hopkins University Methods and related aspects of treating and diagnosing proteinopathies
WO2025193572A1 (en) * 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193770A1 (en) * 2024-03-13 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513811A (ja) 1998-05-06 2002-05-14 ファルマシア・アンド・アップジョン・カンパニー 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のdnaまたは裸のrnaの導入
CA2541006C (en) 2003-10-03 2015-02-17 Brigham And Women's Hospital Tim-3 polypeptides
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP2201120B1 (en) 2007-09-21 2013-12-25 Cadila Healthcare Limited Gcsf fusion protein systems suitable for high expression of peptides
MX374075B (es) 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
US20130267515A1 (en) 2010-10-26 2013-10-10 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2583975A1 (en) 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Agents and methods for the expression and secretion of peptides and proteins
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
EP2792686A1 (en) 2013-04-17 2014-10-22 Heinrich-Heine-Universität Düsseldorf Methods for the expression of peptides and proteins
CN104072615B (zh) 2014-01-26 2016-08-24 中国人民解放军军事医学科学院基础医学研究所 一种能阻断Tim-3信号通路的人Tim-3融合蛋白
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
SG11201606428UA (en) 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
BR102014014502B1 (pt) 2014-06-13 2020-09-15 Ouro Fino Saúde Animal Ltda Vetor de expressão
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
US9710278B2 (en) 2014-09-30 2017-07-18 International Business Machines Corporation Optimizing grouping of instructions
US10016480B2 (en) 2014-10-14 2018-07-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Peptide-based methods for treating pancreatic cancer
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
US9957325B2 (en) 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
CN105504018B (zh) 2016-01-13 2019-01-04 郑州大学 Lag-3亲和肽n13、制备方法及其应用
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018039147A1 (en) 2016-08-23 2018-03-01 The Johns Hopkins University THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR
JP2020514370A (ja) 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
WO2020237050A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
CA3185657A1 (en) 2020-06-04 2021-12-09 Leidos, Inc. Immunomodulatory compounds

Similar Documents

Publication Publication Date Title
JP2022533711A5 (enExample)
JP2020521445A5 (enExample)
US12447213B2 (en) Modulation of novel immune checkpoint targets
JP7395483B2 (ja) mRNAの細胞内送達のためのペプチドおよびナノ粒子
US20190255107A1 (en) Modulation of novel immune checkpoint targets
US10982210B2 (en) Compositions for delivery of cargo to cells
JP7284718B2 (ja) T細胞の機能を調節するためのアンチセンスオリゴヌクレオチド
KR102542533B1 (ko) 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법
JP2023067871A (ja) 癌の免疫療法
JP7187486B2 (ja) Pd-1およびctla-4二重インヒビターペプチド
US20190262399A1 (en) Compositions and methods for evaluating and modulating immune responses
US20200016208A1 (en) Stimulatory Cell Lines For Ex Vivo Expansion And Activation Of Natural Killer Cells
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
CN108779465A (zh) 用于减少pd-l1表达的寡核苷酸
AU2017268399A1 (en) Mrna combination therapy for the treatment of cancer
EP3368689A2 (en) Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
ES3022990T3 (en) Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
JP2023536466A5 (enExample)
CN116529266A (zh) 用于将核酸递送到细胞的组合物和方法
JP2022190026A (ja) Pd-1ペプチド阻害剤
JP2024512669A (ja) タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
JP2017530948A (ja) 抗腫瘍組成物および方法
JP2024532621A (ja) がんを治療するための組成物および方法
JP2023548662A5 (enExample)